Por favor, use este identificador para citar o enlazar este ítem:
https://hdl.handle.net/11000/38908Registro completo de metadatos
| Campo DC | Valor | Lengua/Idioma |
|---|---|---|
| dc.contributor.author | Bermejo Sanz, María del Val | - |
| dc.contributor.author | Meulman, Jessica | - |
| dc.contributor.author | Davanço, Marcelo Gomes | - |
| dc.contributor.author | de Oliveira Carvalho, Patricia | - |
| dc.contributor.author | González-Álvarez, Isabel | - |
| dc.contributor.author | Rossi Campos, Daniel | - |
| dc.contributor.other | Departamentos de la UMH::Ingeniería | es_ES |
| dc.date.accessioned | 2026-01-16T15:39:09Z | - |
| dc.date.available | 2026-01-16T15:39:09Z | - |
| dc.date.created | 2020-06 | - |
| dc.identifier.citation | Pharmaceutics . 2020 Jun 17;12(6):558 | es_ES |
| dc.identifier.issn | 1999-4923 | - |
| dc.identifier.uri | https://hdl.handle.net/11000/38908 | - |
| dc.description.abstract | The aim of the present study was to bring additional evidence regarding a biopredictive dissolution medium containing 1% sodium lauryl sulphate (SLS) to predict the in vivo behavior of carbamazepine (CBZ) products. Twelve healthy volunteers took one immediate release (IR) dose of either test and reference formulations in a bioequivalence study (BE). Dissolution profiles were carried-out using the medium. Level A in vitro-in vivo correlations (IVIVC) were established using both one-step and two-step approaches as well as exploring the time-scaling approach to account for the differences in dissolution rate in vitro versus in vivo. A detailed step by step calculation was provided to clearly illustrate all the procedures. The results show additional evidence that the medium containing 1% SLS can be classified as a universal biopredictive dissolution tool, and that both of the approaches used to develop the IVIVC (one and two-steps) provide good in vivo predictability. Therefore, this biopredictive medium could be a highly relevant tool in Latin-American countries to ensure and check the quality of their CBZ marketed products for which BE studies were not requested by their regulatory health authorities. | es_ES |
| dc.format | application/pdf | es_ES |
| dc.format.extent | 21 | es_ES |
| dc.language.iso | eng | es_ES |
| dc.publisher | MDPI | es_ES |
| dc.rights | info:eu-repo/semantics/openAccess | es_ES |
| dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
| dc.subject | bioequivalence | es_ES |
| dc.subject | biopredictive | es_ES |
| dc.subject | biowaiver | es_ES |
| dc.subject | carbamazepine | es_ES |
| dc.title | In Vivo Predictive Dissolution (IPD) for Carbamazepine Formulations: Additional Evidence Regarding a Biopredictive Dissolution Medium | es_ES |
| dc.type | info:eu-repo/semantics/article | es_ES |
| dc.relation.publisherversion | 10.3390/pharmaceutics12060558 | es_ES |

Ver/Abrir:
In Vivo Predictive Dissolution (IPD) for Carbamazepine Formulations.Additional Evidence.pdf
3,3 MB
Adobe PDF
Compartir:
La licencia se describe como: Atribución-NonComercial-NoDerivada 4.0 Internacional.
.png)